The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk already sells a lower-dose oral formulation of the GLP-1 agonist as Rybelsus for type 2 diabetes ... At the Veeva Commercial Summit in Madrid at the end of 2024, pharmaphorum web ...

Novo Nordisk (NVO) CEO Lars Jørgensen isn't too worried about the upcoming Medicare price negotiations over blockbuster GLP-1 drugs, even though the company still stands with the industry against ...

The Partnership for Safe Medicines went so far as to implore Fox not to broadcast the commercial ... and Rybelsus), patient safety remains our top priority,” Novo Nordisk told Fortune in ...